Latest / Community Health Media
Dr. Caitlin Taylor & Dr. Andrew Davis - Can Camizestrant Change HR+ Breast Cancer Care?
A new approach to treating endocrine resistance may be emerging in metastatic HR-positive breast cancer with the SERENA-6 trial.
Dr. Caitlin Taylor and Dr. Andrew Davis discuss the SERENA-6 trial and the potential role of camizestrant in patients with ESR1-mutated metastatic breast cancer. The conversation explores how ctDNA monitoring may allow clinicians to detect resistance earlier, intervene before radiographic progression, and potentially keep patients on first-line therapy longer.
The discussion covers:
The design and significance of SERENA-6
ESR1 mutations and endocrine resistance…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.